throbber
Nucleic acids research.
`v. 31, no. 11 (June 1 2003)
`General Collection
`W1 NU12.4
`2003-06-23 O7'25:45
`
`x/r-ii 1 IktM
`
`P1/4" IMBER 11 JUNE 1, 2003
`
`is Acids
`Research
`
`NAR
`ONLINE
`
`http://www.nar.emploureals.ors
`
`Transcription
`Endonucelase activity
`
`Packaging
`
`Replication
`
`NAVIONAL
`LIBRARY OF
`ME1)1GINE
`
`rI) IIOATR1161:I 3\FI TAT
`LIBRARY OF
`MEDICINE
`
`NI
`
`4
`
`Cr,
`0'
`0'
`
`u,
`
`ITY PRESS
`
`This materra—Wais copied
`ay be
`41
`Subject US Copyright Laws
`
`' t A0
`
`Alnylam Exh. 1028
`
`04057Z-1 NUCLEIC ACIDS RESEARCH
`2063 VOLUME 31 ISSUE 11
`S ISAC
`
`00
`
`CD
`
`CU
`"4-
`
`O
`
`IND
`5219701
`
`C)
`CIO"
`
`(cid:9)
`(cid:9)
`

`

`Subscriptions
`
`Nucleic Acids Research is published twice monthly (24 issues per year).
`Subscriptions are entered on a calendar year basis only and are available as a
`printed version (including online access) or as online access only at a discount of
`10% (+VAT in UK). Prices include postage by surface mail or, for subscribers in
`the USA and Canada by air freight, or in India, Japan. Australia and New Zealand.
`by Air Speeded Post. Airmail rates are available on request.
`
`Annual subscription rate (Volume 31, 2003):
`Insritutionai
`Print and Online site licence: UK and Europe £1365, Rest of World $2360.
`Personal
`Print and Online: UK and Europe £365, Rest of World $621.
`Back volume prices arc available on request. Please add sales tax to the prices
`quoted.
`
`Orders, Orders and payments from, or on behalf of, subscribers in the various
`geographical areas shown below should he sent to the Press office indicated.
`
`The Americas: Oxford University Press Inc.. 2001 Evans Road. Cary, NC 27513.
`USA.
`
`Rest of the World: Journals Subscriptions Department, Oxford University Press.
`Great Clarendon Street, Oxford OX2 6DP, UK.
`Tel: (+441865 or 01865) 353907; Fax: (+441865) 353485;
`Entail: jnl.ordersontip.co.tik
`
`Advertising. To advertise in Nucleic Acids Research contact Oxford University
`Press (US office) in the Americas or Oxford University Press (UK office) in the
`Rest of the World (see addresses above).
`
`Oxford University Press 2003. All rights reserved; no pan of this publication
`may be reproduced. stored in a retrieval system, or transmitted in any form or by
`any means, electronic, mechanical, photocopying, recording, or otherwise without
`either prior written permission of the Publishers, or a licence permitting restricted
`copying issued in the UK by the Copyright Licensing Agency Ltd. 90 Tottenham
`Court Road, London WM 9HE, or in the USA by the Copyright Clearance Center,
`222 Rosewood Drive, Danvers, MA 01923. USA.
`
`Back volumes of this journal are available in 16 min microfilm, 35 non microfilm
`and 105 microfiche from University Microfilms International, 300 North Zeet,
`Road, Ann Arbor, MI 48106-1346, USA. Copies of articles published are also
`available from UNIT.
`
`Nucleic Acids Research (ISSN 0305-1048) is published twice monthly by Oxford
`University Press, Oxford, UK. Annual subscription price is US$2360. Nucleic
`Acids Research is distributed by Mercury International. 365 Blair Road, Avenel,
`NJ 07001, USA. Periodicals Postage Paid at Rahway, NJ, USA and additional
`entry points.
`
`US POSTMASTER: send address corrections to Nucleic Acids Research, efo
`Mercury Airfreight international Ltd. 365 Blair Road, Avenel, NJ 07001, USA.
`
`Typeset and printed by Information Press Ltd. Oxford, UK on acid-free paper.
`
`Cover: Two promoter structures of influenza A virus. The upper one is the viral promoter and the lower one is the cRNA
`promoter, which is the replicative intermediate. The working hypothesis from our work is that the same RdRp regulates viral
`replication by interacting with distinct hut similar promoter structures. The internal loops of both RNA promoters provide
`common protein binding sites. However, the structural and dynamic differences within the vRNA and cRNA promoters may
`induce two distinct RNP conformations. For further information see the paper by Park et al. in this issue [Nucleic Acids Res.
`(2003) 31, 2824-28321.
`
`This material wascopied
`at the NLM and may be
`Subject US Copyright Laws
`
`

`

`clleic Acids Research
`
`Volume 31 number 11, June 1, 2003
`
`Contents (cid:9)
`
`CHEMISTRY
`
`Syntheses and structural studies of ealix[4]arene—
`nucleoside and cali441arene—oligonucleolide hybrids
`
`S.J.Kim and B.H.Kim
`
`2725-2734
`
`S (cid:9)
`
`Steric inhibition of human intmunodeficieney virus
`type-1 Tat-dependent trans-activation in van) and in
`cells by oligonuclentides containing 2`.0-methyl
`0-clamp ribunueleoside analogues
`
`COMPUTATIONAL BIOLOGY
`
`Jl (cid:9) Using structural motif templates to identify proteins
`with DNA binding function
`
`SPINE 2: a system for collaborative structural
`proteomics within a federated database framework
`
`jty (cid:9)
`
`Integrated functional and bioinformatics approach for
`the identification and experimental verification of
`RNA signals: application to HIV-1 INS
`
`ri (cid:9)
`
`Efficient clustering of large EST data sets on parallel
`computers
`
`GENOMICS
`
`S.C.Holmes, A.A.Arzumanov and M.I.Gait
`
`2759-2768
`
`S.Jones,1.A.Barker, l.Nobeli and J.M.Thornton
`
`2811-2823
`
`C.-S.Goh, N.Lan, N.Echols, S.M.Douglas, D.Milburn, (cid:9)
`P.Bertone, R.Xiao, L.-C.Ma, D.Zheng, Z.Wunderlich,
`T.Acton, GT,Montelione and M.Gerstein
`
`2833-2838
`
`H.Wolff, R.Brack-Werner, M.Neumann, T.Wemer and (cid:9)
`R.Schneider
`
`2839-2851
`
`A.Katyanaraman, S,Alum, S.Kodiari and V.Brendel (cid:9)
`
`2963-2974
`
`Faithful expression of a tagged MTH WT1 protein
`from a genomic transgene in zebrafish: efficient
`splicing of pufferfish genes in zebrafish but not mice
`
`C.G.MRes, L.Rankin, (cid:9)
`N.D.Hastie
`
`M.Niksie, G.Elgar and (cid:9)
`
`2795-2802
`
`MOLECULAR BIOLOGY
`
`Transcriptional regulation of the human MW-la
`promoter by RUNX1 and MOZ
`
`C.A.P.Bristow and P.Shore (cid:9)
`
`Effect of DNA bases and backbone on 070 holoenzyme
`binding and isomeritation using fork junction probes
`
`M.S.Fenton and I.D.Gralla (cid:9)
`
`Overcxpression of FABP7 in Down syndrome fetal
`brains is associated with PKNOKI gene-dosage
`imbalance
`
`Domain mapping of Escherichia coil RecQ defines the
`roles of conserved N- and C-terminal regions in the
`RecQ family
`
`UVA-induced cyclobutane pyrimidinc (timers form
`predominantly at thymine—thyrnine dipyrimidines and
`correlate with the mutation spectrum in rodent cells
`
`M.F.Stinchez-Font, A.Bosch-Comas, R.Gonxiilez-Duarte (cid:9)
`and G.Marfany
`
`D.A.Bemsteitt and 1.L.Keck (cid:9)
`
`R.Drnuin, D.Perdiz,
`P.J.Rochette, (cid:9)
`N.Bastien, E.A.Drobeisky and E.Sage
`
`Purification and characterisation of a novel 1)NA
`mclityltransferase, M.AlidE
`
`P.Marks, .1.McGeehan, G,Wilson, N,Errington and (cid:9)
`G.Kneale
`
`2735-2744
`
`2745-2750
`
`2769-2777
`
`2778-2785
`
`2786-2794
`
`2803-2810
`
`Continued
`
`This material was copied
`at the NLM and maybe
`Subject US Copyright Lens
`i
`
`

`

`Contents (Continued)
`
`•
`
`•
`
`The Drosophila Corti protein interacts with
`Polycomb-group proteins and the GAGA factor
`
`Experimental and computational analysis of
`transcriptional start sites in the cyanobacterium
`Prochlorocorcas MED4
`
`ZBP-89 represses vimentin gene transcription by
`interacting with the transcriptional activator, Spl
`
`A new member of the MCIVI protein family encoded
`by the human MeM8 gene, located contrapodal to
`GCDIO al chromosome band 20p12.3-1.3
`
`A novel engineered meganuclease induces homologous
`recombination in yeast and mammalian cells
`
`RNA
`
`Structural variations and stabilising modifications of
`synthetic siRNAs in mammalian cells
`
`Insight into the mechanism of the peptide-haled gene
`delivery system MPG: implications for delivery of
`siRNA into mammalian cells
`
`'the phage T4 restriction endorihonuelease RegII:
`a eyelizing enzyme that requires two histidines to be
`fully active
`
`Tertiary structure base pairs between D- and
`Tye-loops of Escherichia roll IRNAL" play important
`roles in both aminnacylution and editing
`
`Optimisation of the 10-23 DNAzyme-substrate pairing
`interactions enhanced RNA cleavage activity at
`purine-cylosine target sites
`
`Volume 31 number 11, June 1, 2003
`
`J.Salvaing. Alopez, A.Boivin, J.S,Deutsch and
`FTeronneu
`
`J.Vogel, I.M.Asmann, H.Herzel and W.R.Hess
`
`X.Zhang. I.H.Diah and Z.E.Zehner
`
`E.M.Johnson, Y.Kinoshita and D.C.Danicl
`
`S.Arnould, P.Chames, P.Rochais, (cid:9)
`D.Desfontaines, C.Puzin, A.Patin, A.Zanghellini, F.Paques
`and E.Lacroix
`
`F.Czautlema, M.Fechtner, S.Dames, H.Ayglin, A.Klippel,
`G.J.Pronk, K.Giese and ].Kaufmann
`
`F.Simeoni, M.C.Mnrris, F.Heitz and G.Divita
`
`F.Salda. M.Dzaru and F.Bontems
`
`X.Du and E.-DAVang
`
`2873-2882
`
`2890-2899
`
`29(10-2914
`
`2915-2925
`
`2952-2962
`
`2705-2716
`
`2717-2724
`
`2751-2758
`
`2865-2872
`
`M.I.Cairns, A.King and L-Q.Sun
`
`2883-2889
`
`S Exploring the repertoire of RNA secondary motifs
`using graph theory; implications for RNA design
`
`H.H.Gan, S.Pasquali and T.Schlick
`
`2926-2943
`
`STRUCTURAL BIOLOGY
`
`Solution structure of the influenza A virus cl2NA
`promoter: implications for differential recognition of
`viral promoter structures by RNA-dependent RNA
`polymerase
`
`The role of intercalating residues in chromosomal
`high-mobility-group protein DNA binding, bending
`and specificity
`
`S Specific interactions of distamycin with 6-quadruples
`DNA
`
`METHODS
`A novel helper plunge that improves phage display
`selection efficiency by preventing the amplification of
`plunges without recombinant protein
`
`C.-J.Park, S.-H.Bae, (cid:9)
`
`G.Varani and B.-S.Choi
`
`2824-2832
`
`J.Klass, E.V.Murphy 1V, &Fouts, M.Serenil, A.Changela,
`J.Siple anti M.E.A.Churchill
`
`2852-2864
`
`M.J.Cocen, L.A.Hanakahl, M.D.Huber and N.IVIaizels
`
`2944-2951
`
`R.A.Kramer, F.Cos, M.van der Horst,
`S.van den Oudenrijn, P.C.M.Res, J.Bia, T.Logtcnbcrg and
`J.dc Kniif
`
`e59 (9 pp.)
`
`Court/nit&
`
`I
`
`This material %sea copied
`at the NUN and may ere
`Subject US Copyright Laws
`
`ii
`
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`

`

`Contents (Continued)
`
`Volume 31 number 11, June 1, 2003
`
`Use of a three-color eDNA microarray platform to
`measure and control support-bound probe for
`improved data quality and reproducibility
`
`Precise determination Of mitochondria' DNA copy
`number in human skeletal and cardiac muscle by a
`PCR-based assay: lack of change of copy number with
`age
`
`A novel multiplex quantitative DNA array based l'CR
`(MQDA-PCR) for quantification of transgenic maize
`in food and feed
`
`MALDI mass spectrometry analysis of single
`nucleotide polymorphisms by photocleavage and
`charge-tagging
`
`M..1Messner, X.Wang. S.Khan. L.Mcycr, M.Schlicht. (cid:9)
`J.Tackes. M.W.Datta, H.J.Jacoh and S.Ghosh
`
`c60 (9 pp.)
`
`F.I.Miller, F.L.Rosenfeldt, C.Zhang, A.W.Linnane and (cid:9)
`P.Nagley
`
`e61 (8 pp.)
`
`K.Rudi, I.Rud and A.Floick (cid:9)
`
`e62 (8 pp.)
`
`S.Sauer. H.Lcliruch and R.Reinhardt (cid:9)
`
`e63 (10 pp.)
`
`In vitro analysis of nuclear niRNA export using
`molecular beacons for target detection
`
`R.II.Kchlenhacit (cid:9)
`
`An automated microplate-based method for
`monitoring DNA strand breaks in plasmids and
`bacterial artificial chromosomes
`
`Genotyping single nucleotide polyntorphisms directly
`from genomic DNA by invasive cleavage reaction on
`microsplieres
`
`AUTHOR INDEX
`
`Ze4 cmaains a novel method
`S, Supplementary Material rivailable at NAR Online
`
`C.Rock, P.Ayazi Shamlou and M.S.Levy (cid:9)
`
`e64 (8 pp.)
`
`c65 (6 pp.)
`
`K.V.N.Rao, P.Wilkins Stevens, J.G.1-14, V.LyanUcliev, (cid:9)
`B.P.Neri and D.M.Kelso
`
`e66 (8 pp.)
`
`This material was copied
`at the NLM and may be
`Subject US Copyright Laws
`(cid:76)(cid:76)i
`
`(cid:9)
`

`

`Nucleic Acids Research, 2003, Vol. 31, No. II 2705-2716
`DOI: 10.1093InarIgkg393
`
`Structural variations and stabilising modifications of
`synthetic siRNAs in mammalian cells
`Frank Czauderna, Melanie Fechtner, Sibylle Dames, Hilseyin Aygunl, Anke Klippel,
`Gijsbertus J. Pronk, Klaus Giese and Jorg Kaufmann*
`
`Atugen AG, Otto Warburg Haus (No. 80), Robert-Roessle-Strasse 10, 13125 Berlin, Germany and 1BioSpring,
`Hanauer Landstrasse 526, 60386 Frankfurt, Germany
`
`Received March 20, 2003; Revised and Accepted April 11, 2003
`
`ABSTRACT
`Double-stranded short interfering RNAs (siRNA)
`induce post-transcriptional silencing in a variety of
`biological systems. In the present study we have
`investigated the structural requirements of chemic-
`ally synthesised siRNAs to mediate efficient gene
`silencing in mammalian cells. In contrast to studies
`with Drosophila extracts, we found that synthetic,
`double-stranded siRNAs without specific nucleotide
`overhangs are highly efficient in gene silencing.
`Blocking of the 5'-hydroxyl terminus of the anti-
`sense strand leads to a dramatic loss of RNA inter-
`ference activity, whereas blocking of the 3' terminus
`or blocking of the termini of the sense strand had
`no negative effect. We further demonstrate that syn-
`thetic siRNA molecules with internal 2'-0-methyl
`modification, but not molecules with terminal modi-
`fications, are protected against serum-derived
`nucleases. Finally, we analysed different sets of
`siRNA molecules with various 2'-0-methyl modifica-
`tions for stability and activity. We demonstrate that
`2'-0-methyl modifications at specific positions in
`the molecule improve stability of siRNAs in serum
`and are tolerated without significant loss of RNA
`interference activity. These second generation
`siRNAs will be better suited for potential therapeutic
`application of synthetic siRNAs in vivo.
`
`INTRODUCTION
`The term RNA-mediated interference (RNAi) was initially
`introduced by Fire and co-workers (1) to describe the
`observation that injection of double-stranded RNA (dsRNA)
`into the nematode Caenorhabditis elegans can block expres-
`sion of genes highly homologous in sequence to the delivered
`dsRNA. RNAi is evolutionarily conserved among cukaryotes
`and it appears to have an essential role in protecting the
`genome against invasion by pathogens such as viruses, which
`generate dsRNA molecules upon activation and replication
`(2). Most recently two independent studies demonstrated that
`the yeast RNAi machinery is required for the formation and
`
`maintenance of heterochromatin during mitosis and meiosis,
`indicating additional functions for RNAi (3,4). In the past,
`repression of genes by long dsRNAs has been less successful
`in mammalian cells with the exception of embryonic cells
`(5,6). Use of short (<30 nt) synthetic dsRNAs allowed for
`sequence-specific gene silencing yet avoided the non-selective
`toxic effects of long dsRNAs in differentiated mammalian
`cells (7). This discovery triggered a much wider interest in the
`RNAi phenomenon since it provides a new avenue for loss of
`function studies in somatic cells of vertebrates. Initial studies
`with these small interfering RNAs (siRNAs) demonstrated
`that the duplex must have 2 or 3 nt overhanging 3' ends for
`efficient cleavage destruction of the target mRNA (8). The 3'
`overhangs can be generated by cleavage of long dsRNA into
`siRNAs by a multidomain RNase III-like enzyme, known as
`Dicer (9). In a subsequent step the siRNA associates with the
`RNAi-induced silencing complex (RISC), which is then
`guided to catalyse the sequence-specific degradation of the
`mRNA (9-11).
`RNAi induced by synthetic siRNAs is transient, and in
`mammalian cell culture systems re-expression of the target
`mRNA usually occurs after a few days (12,13). Therefore an
`improvement in the intracellular and extracellular stability of
`the effector molecules will be one crucial aspect for the
`successful in vivo application of synthetic siRNAs. A variety
`of chemical modifications, including terminal and internal
`modifications (e.g. 2'43-modification or phosphorothioate
`linkages), have been tested to see whether they influence
`RNAi inducing activity (7.8,13-15). However, these studies
`did not adequately assess the effect of the different modifi-
`cations on sensitivity of these molecules to siRNA-degrading
`serum-derived nucleases.
`In the present work we define the minimal structural
`requirements of siRNAs in mammalian cells and test a series
`of chemical modifications to improve the stability of siRNAs
`for future in viro applications. To determine differences in
`potency, we measured the inhibition of expression of several
`targets, including PTEN, p HOD and Akt 1, which are all
`members of the phosphatidylinositol (PI) 3-kinase pathway
`(16,17). Surprisingly, we found no overhang dependence of
`the siRNA duplexes in HeLa cells, which is in contrast to
`observations made in the Drosophila system (15). We have
`established the minimal required size for functional siRNAs in
`WU cells and have developed functionally active siRNA
`
`*To Whom correspondence should be addressed. Tel: +49 30 9489 2833; Fax: +49 30 9489 2801; Email: kaufmann@atugen.com
`
`Nucleic Acids Research, Vol. 31 No. I1 © Oxford University Press 2003; all rights reserved
`
`This material was copied
`
`

`

`2706 Nucleic Acids Research, 2003, Vol. 31, No. 11
`
`molecules with increased nuclease resistance. Our results
`provide a basis for the further development of synthetic siRNA
`molecules with improved characteristics, including higher
`resistance to serum-derived endonucleases.
`
`MATERIALS AND METHODS
`
`Synthetic siRNAs and GeneBlocs
`Synthetic siRNAs were purchased from BioSpring (Frankfurt,
`Germany). The oligoribonucleotides were resuspended in
`RNase-free TE to a final concentration of 50 p.M. In the case of
`bimolecular siRNA molecules, equal aliquots (100 p.M) were
`combined to a final concentration of 50 p.M. For the formation
`of duplexes the siRNAs were incubated at 50°C for 2 min in
`annealing buffer (25 mM NaCI, 5 mM MgC12) and were
`cooled down to room temperature. The PTEN-specific
`the schematic structure cap-
`Gene Blocs used have
`nnnnnnNNNNNNNNnnnnnn-cap, as published previously
`(16), where cap represents an inverted deoxy abasic modifi-
`cation, n stands for 2`-0-methyl ribonucleotides (A, G, U or C)
`and N represents phosphorothioate-linked deoxyribonucleo-
`tides (A, G, T or C).
`
`Cell culture and transfections
`
`The particular HeLa cell line used in the experiments
`presented was a gift from M. Gossen (MDC, Berlin,
`Germany) and was grown in Eagle's minimum essential
`medium with 2 mM L-giutamine, Earle's balanced salt
`solution, 1 mM sodium pyruvate, 0.1 mM non-essential
`amino acids and 10% fetal bovine serum (FBS). Synthetic
`siRNA and antisense GeneBloc transfections were carried out
`in 96-well or 10 cm plates (at 30-50% confluency) by using
`cationic lipids such as Oligofectamine (lnvitrogen, Carlsbad,
`CA) or NC388 (Atugen, Berlin, Germany) as reported
`previously (16). HeLa cells were transfected by adding a
`pre-formed 5X concentrated complex of siRNAs and lipid in
`serum-free medium to cells in complete medium. The total
`transfection volume was 100 pl for cells plated in 96-wells and
`10 ml for cells in 10 cm plates. The final lipid concentration
`was 0.8-1.2 pg/m1 depending on cell density; the siRNA
`concentration is indicated in each experiment.
`
`Antibodies and immunoblotting
`
`Cell lysates were prepared and aliquots of the cell extracts
`containing equal amounts of protein were analysed by
`immunoblotting as described previously (16,17). The murine
`monoclonal anti-pl 10a antibody has been described (18).
`Rabbit polyclonal anti-Akt and anti-phospho-Akt (S473)
`antibodies were obtained from Cell Signalling Technology.
`The murine monoclonal anti-PTEN antibody was from Santa
`Cruz Biotechnology.
`
`Quantitation of mRNA by Tagman analysis
`The RNA of cells transfected in 96-wells was isolated and
`purified using the lnvisorb RNA HTS 96 kit (InVitek GmbH,
`Berlin, Germany). Inhibition of targeted mRNA expression
`was detected by real time RT—PCR (Taqman) analysis using
`300 nM 5' forward primer, 300 nM 3' reverse primer and
`100 nM Fam-Tamri-labelled Taqman probe. The gene-
`specific primer sequences can be obtained on request. The
`
`reaction was carried out in 50 pl and assayed in an ABI
`PRISM 7700 Sequence detector (Applied Biosystems) accord-
`ing to the manufacturer's instructions under the following
`conditions: 48°C for 30 min, 95°C for 10 min, followed by
`40 cycles of 15 s at 95°C and 1 min at 60°C.
`
`Nuclease resistance assay
`For the stability assay 5 pl of (2.5 p.M) siRNA was incubated
`in 50 p.1 of fetal bovine serum for 15 or 120 min at 37°C. The
`solution was extracted with phenol and siRNA was precipi-
`tated with ethanol and separated on 10% polyacrylamide gels
`followed by ethidium bromide staining. Equal amounts of
`siRNA before serum incubation (0 min) was extracted with
`phenol in parallel and loaded as an input control.
`
`RESULTS
`
`Comparison of synthetic siRNAs and antisense molecules
`in HeLa cells
`As most published studies with siRNA in mammalian cells
`have involved the knock-down of ectopically or abundantly
`expressed genes, we first set out to demonstrate that synthetic
`siRNAs can be efficient tools in reducing endogenous mRNA
`and protein levels. For this purpose we designed and analysed
`siRNA molecules specific for the tumour suppressor PTEN.
`For comparison and as a positive knock-down control, we
`employed in parallel conventional antisense molecules
`containing the same nucleotide sequences. The antisense
`molecules, here called GeneBlocs, consisted of nine internal
`deoxyribonucleotides for activation of RNase H flanked by six
`2`-0-methyl-modified ribonucleotides, whereas the siRNAs
`used consisted of two 21mer ribonucleotides with two
`deoxythymidine nucleotides at the 3' termini (Fig. IA). The
`double-stranded siRNA as well as the single-stranded
`GeneBlocs are identical in length (21mer + terminal modifi-
`cations). To control for non-specific transfection effects, we
`included mismatch sequences as negative controls. HeLa cells
`were transfected with increasing amounts of these molecules
`and the PTEN mRNA level was analysed 24 h later by real
`time PCR (Taqman). The maximal reduction of PTEN mRNA
`normalised to the mRNA of p 1 10a, one of the catalytic
`subunits of PI 3-kinase, was reached with 2.2 nM siRNA and
`20 nM GeneBloc (Fig. 1B). To verify the result on the mRNA
`level, we analysed protein reduction induced by antisense
`GeneBloc and siRNA transfection in a second set of experi-
`ments. HeLa cells were transfected with increasing amounts of
`these molecules and cell lysates were analysed 48 h later by
`immunoblot analysis using PTEN-specific antibodies. p110a
`protein level served as a loading control (Fig. 1C). Maximal
`PTEN protein knock-down was detected with 2.5 nM
`siRNA and 15 nM GeneBloc. These experiments demonstrate
`that siRNA molecules can efficiently reduce mRNA and
`protein levels of endogenous genes. Furthermore, these
`siRNAs can be more efficient in mediating mRNA
`reduction when compared to conventional antisense molecules
`directed against the same target sequence. The observed
`differences in efficacy may he due to different mechanisms
`of target recognition and/or degradation and may reflect
`the involvement of more efficient catalytic steps in the case
`of RNAi.
`
`This material Was copied
`at the N LIM and may he
`Subject US Copyright Laws
`
`

`

`Nucleic Acids Research, 2003, Vol. 31, No. I1 2707
`
`35nM
`8,75nM
`0 2,2nM
`0,55nM
`0,13nM
`• 0 03nM
`
`El 40nIVI
`Cj 20nM
`10nM
`5nM
`
`siRNA
`
`UT PTEN PTEN
`1AB 1ABMM
`
`GeneBloc
`
`UT PTEN PTEN
`GB GBMM
`
`1,2 (cid:9)
`1
`0,8 -
`0.6 -
`0,4
`0,2 -
`
`1,2 (cid:9)
`
`0,8
`0,6
`0,4
`0,2
`0
`
`Ratio PTEN / p110a
`
`Ratio PTEN I pl lea
`
`B
`
`A
`
`C
`
`PTEN1A (cid:9)
`PTEN18 (cid:9)
`
`PTENIAMM (cid:9)
`PTEN1BM4 (cid:9)
`
`cquuagcagnamcaamaggag-TT
`3' TT-geramegucuulsguuuuccue
`
`V V V V
`cgugavacaaagatamaugag-TT
`TT-gancuesnaguuutuulluBauc
`
`?TEN GB (cid:9)
`
`PTEN G5t'5 (cid:9)
`
`5' (cid:9)
`
`5' (cid:9)
`
`iB-cmcguuTTCTTTCTGcunacg-i8
`
`VYVV
`iB-cmcauuTTETTTGTGBucacq-i8
`
`GeneBloc (cid:9)
`
`siRNA
`
`UT 0.9 3.7 15 60 0.15 0.6 2.5 10 nM
`
`p11 OCL — (cid:9)
`
`.....
`
`PTEN — ammo._ •••••
`
`1 2 3 4 5 6 7 8 9
`
`Figure 1. mRNA and protein knock-down of endogenous PTEN and induced by transfectien of siRNA or GeneIlloe (GB, antisense) in HeLa cells. (A) The
`sense (A) and antisense (B) strands of siRNA targeting human PTEN mRNA are shown in comparison to the corresponding GeneBloc (antisense molecules).
`siRNAs were synthesised with 2 nt deoxythymidine (TT) 3' overhangs. GcneBlocs representing the third generation of antisense oligonucleotides with
`inverted abasic (ID) end modifications (see Materials and Methods). The sequences of the respective mismatch controls tMM) containing 4 nt changes are
`shown. (II) Reduction of PTEN mRNA expression in siRNA- and GeneBloc-transfected HeLa cells. HeLa cells were transfected with the indicated amounts
`of siRNA and Genefiloc as described. After 24 h, RNA was prepared and subjected to real time RT—PCR (Taman) analysis to determine PTEN niRNA
`levels relative to ph lOcc mRNA levels. Each bar represents triplicate transfections (I' SD). (C) inhibition of PTEN protein expression analysed by
`immunoblot. The cells were harvested 48 h after transfection of the indicated amounts of GeneMocs or siRNAs. Cell lysates were separated by SOS—PAGE
`and analysed by immunobioning using anti-PTEN and anti-pl 10a antibody. The amount of p1 10a, a catalytic subunit of P1 3-kinase, was used as a loading
`control. Control cell extract from untransfectes.1 HeLa cells (UT) were loaded in the left lane.
`
`No overhang requirements of siRNA duplexes in
`mammalian cells
`The structural—functional relationship of siRNAs has been
`extensively studied biochemically using Drosophila melano-
`gaster embryo lysates (7,15). Using this system it has been
`demonstrated that duplexes with 2 nt 3' overhangs were the
`most efficient triggers of inRNA degradation (8,15,19). To test
`whether a similar dependence is true for mammalian cells, we
`transfected PTEN siRNA molecules with 3' or 5' overhangs or
`without overhangs into HeLa cells. Surprisingly, we did not
`observe a more efficient knock-down of target RNA with
`siRNAs containing 3' overhangs when compared to blunt
`molecules or those with 5' overhangs (Fig. 2A). Similar results
`were obtained for the second target pi 1013 (Fig. 2C). To verify
`the observed inRNA knock-down, we performed an iminuno-
`blot analysis using PTEN-specific antibodies (Fig. 2B). In
`these experiments the reduction of PTEN protein expression
`as well as the downstream phosphoryiation of Aktl kinase, a
`consequence of PTEN protein inhibition (16,17), was very
`similar with the different siRNA duplexes. We concluded
`from these data that 3' overhangs on synthetic siRNAs arc not
`essential for RNAi in HeLa cells.
`
`Duplex length requirements Of siRNA duplexes in
`mammalian cells
`We next examined the effects of duplex length variations on
`siRNA activity. For these experiments we used the Aktl
`kinase as a target. Duplexes of 19 nt length were highly
`efficient in reducing Aktl mRNA levels independent of the
`nature (deoxyrihonucleotides or rihonucleotides) of the 3'
`overhang (Fig. 3A, compare molecules 1AB, 2AB, 3AB and
`4AB). This result is consistent with our observation that a 3'
`overhang appears not to be crucial for siRNA function in HeLa
`cells. Next we reduced the duplex length to 17 nt (Fig. 3A,
`molecule 5AB). This molecule did show a dramatically
`reduced silencing activity, suggesting that active siRNA
`duplexes must have a minimal length (-19 nt), which is in
`agreement with experiments assessing activity of siRNA
`molecules with different duplex lengths in Drosophila extracts
`(15). This minimal duplex length for active siRNA molecules
`might be explained mechanistically by two different require-
`ments. First, a minimal base pairing between the antisense
`siRNA and the target mRNA may be obligatory or, second,
`incorporation into the RISC requires a minimal length of the
`siRNA duplex. To address this question we synthesised and
`
`This material was copied
`at the NLM and may be
`Subject US Copyright Laws
`
`(cid:9)
`

`

`2708 Nucleic Acids Research, 2003, Vol. 31, No. 11
`
`A
`
`B (cid:9)
`
`C
`
`Ratio PTENip110a
`N.)
`c) v s (cid:9)
`N Zn
`
`o 25nM
`o 5nM
`o 1nM
`0.2nM
`
`PTEN1A (cid:9)
`PTEN1B (cid:9)
`
`PTEN1AK4 (cid:9)
`PTEN1SK1 (cid:9)
`
`cguuagcagaaac aaa aggag- TT
`5' (cid:9)
`3' TT-gcaaucgucuuugummccuc
`
`3
`
`V
`.! (cid:9)
`•
`CgugagcaCaaagaaaaugag -TT
`5' (cid:9)
`3' TT-gcacucguguuucuuuuacuc
`
`Cguuagcagaaacaaaaggag
`5" (cid:9)
`PTEN2A (cid:9)
`PTEN28 3' gcsaucgucuungummccuc
`
`PT EN2A114 (cid:9)
`PTEN2131-23 (cid:9)
`
`PTEN3A (cid:9)
`PTEN313 (cid:9)
`
`•
`3 VT (cid:9)
`agugagcacaaagaaaaugag
`gcacucgugULMCUuuuacuc
`
`5' TT-cguuagcagaaacaaaaggag
`gcaau cgu cutzugUmm C CU c- TT
`3' (cid:9)
`
`PTEN3A1111 (cid:9)
`PTEN3E2.41 (cid:9)
`
`•
`11,
`1'
`•
`5' TT-cgugagcacaaagaaaaugag
`gcacucgugUllucUUuuacuc-TT
`3' (cid:9)
`
`UT lAB 1A13 2AB 2AB 3AD 3AB GB GB
`MM (cid:9)
`MM
`MM (cid:9)
`MM (cid:9)
`
`pi 10“. — (cid:9)
`
`1"mi
`
``""., ••••.. (cid:9)
`
`••••••
`
`PTEN
`
`P*-Akt
`
`.•1=•=1•
`
`••••••.•
`
`1 2 3 4 5 6 7 8 9
`
`Ratio p11013/ pliOct
`o o o c>
`IV
`-a) (cid:9)
`-4).
`
`s)
`
`p110131A (cid:9)
`1)1.1.0pia (cid:9)
`
`uggaaugaaccacuggaauuu-TT
`5' (cid:9)
`3' TT-accuuacuuggugaccuuaaa
`
`TV! (cid:9)
`•
`ginolDisadm
`5' ugguaucaagaucaggaauau-TT
`pllOPTEM 3' TT-accauaguucgagucCUUalla
`
`p13.0132A (cid:9)
`p1101325 (cid:9)
`
`p110133A (cid:9)
`p110133B (cid:9)
`
`uggaaugaacCaCUggaauuu
`accuuacuuggugaccuuaaa
`
`3' (cid:9)
`
`5' TT-uggaaugaaccacuggaauuu
`nccuuacuuggugaccuuaaa-TT
`
`UT
`
`Figure 2. siRNA duplexes with a 3' or 5' overhang or without overhang (blunt) arc equally potent in mediating gene silencing in HeLa cells. (A) Inhibition
`of PTEN mRNA expression in HeLa cells transfected wills the indicated amounts of siRNA molecules. The sequences and different terminal structures of the
`siRNAs molecules are shown on the left. Mutations in the mismatch molecules are indicated by arrowheads. Samples were analysed in parallel for the level
`of PTEN mRNA expression 24 h after transfection by real time RT—PCR (Taqman) analysis. PTEN mRNA levels are shown relative to the mRNA levels of
`pl Ulla, which served as internal reference. Each bar represents triplicate transfections (± SD). (B) Inhibition of PTEN protein expression by use of siRNAs
`with different terminal structures. The cells were harvested 48 h after transfeetion of the indicated siRNAs (30 nM) (lanes 2-7) or GeneBlocs (30 nM) (lanes
`8 and 9). Cell extracts were separated by SDS—PAGE and analysed by immunoblotting using anti-010o., anti-PTEN or anti-phospho-Akt antibody. The
`amount of pl lOcx was used as a loading control and control cell extracts from untransfected HeLa cells (UT) were loaded in lane t. (C) Inhibition of pl
`mRNA expression in HeLa cells transfected with the indicated amounts of siRNA molecules. pl l03 mRNA levels are shown relative to the inRNA levels of
`pl Ma, which served as internal reference. The ratio of p11013/p110a inRNA of untransfected HeLa cells is shown at the bottom (UT). Each bar represents
`triplicate transfectinns (I- SD).
`
`transfected 19 nt long siRNA duplex molecules with one and
`two terminal mutations (CG and UA inversion) relative to the
`wild-type sequence (Fig. 3A, molecules 6AB and 7AB), Both
`
`molecules, even the molecule with a stretch of only 15 nt base
`pairing to the target mRNA, were functional in reducing the
`Aktl tnRNA level. We concluded from this result that the
`
`This material was copied
`at the HIJA and maybe
`su bject US Copyr ight Laws
`
`

`

`A
`
`Aktl 1A (cid:9)
`Aktl 18 (cid:9)
`
`cgaggggaguacaucaaga-uu
`5' (cid:9)
`3' uu-gcuecccucauguaguucu
`
`cgaggggaguacaucaaga-cc
`5' (cid:9)
`3" uu-gcuccccucauguaguucu
`
`cgaggggaguaoaucaaga-CC
`5' (cid:9)
`3' TT-gcuccccucauguaguucu
`
`cgaggggaguacaucaaga-TT
`5' (cid:9)
`3' TT-gcuceccucauguaguucu
`
`gaggggaguacaucaaq-ac
`5' (cid:9)
`3' ug-cuccocucauguaguuc
`•
`ggaggggaguacaucaagu-TT
`5' (cid:9)
`3" TT-ccuccccucauguaguuca
`Iry (cid:9)
`if
`geaggggaguacaucaaou-TT
`5" (cid:9)
`3' TT-cgucaccucauguaguuga
`
`Aktl 2A (cid:9)
`Aktl 28 (cid:9)
`
`Aktl 3A (cid:9)
`Aktl 38 (cid:9)
`
`Aktl 4A (cid:9)
`Akt1 48 (cid:9)
`
`Aktl SA (cid:9)
`Aktl 58 (cid:9)
`
`Aktl (cid:9)
`Aktl 68. (cid:9)
`
`Aktl 7A (cid:9)
`Aktl 73 (cid:9)
`
`PTEN lA (cid:9)
`PTEN 18 (cid:9)
`
`Nucleic Acids Research, 2003, Vol. 31, No. 11 2709
`
`Duplex length (cid:9)
`
`Ratio Aktl p1 lOcc
`
`is. C) Ca •-•
`
`19mer
`
`19mer
`
`19mer
`
`19mer
`
`17mer
`
`19nner(2MM)
`
`19nner(4MM)
`
`cguuagcagaaacaaaaggag -TT
`5" (cid:9)
`3" TT-gcaaucgucuuuguuuuccuc
`
`21mer
`
`Ratio PTEN/p1lOcc
`
`UT
`
`40nM
`o 20nM
`O 10nM
`▪ 5nM
`
`ATENA
`PTENB
`
`PTENMM1
`PTENMM1
`
`PTENMM2
`PTENMM2
`
`PTENMM3
`PTENHHIG
`
`PTEMMK4
`PTEMMK4
`
`5'guuagcagaaacaaaagga
`3'caaucgucuuuguuuuccu
`•
`5'guuagcagaaagaaaagga
`3 caaucgucuuucuuuuccu
`
`5 4 guuagcaaaa;aaaagga
`3"caaucguguuucuuuuccu
`
`3 V V
`5 .guuaccacaaagaaaagga
`3' caaugguguuuC

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket